- A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to enhance cancer immunity
BP1209 is a proprietary, advanced cancer vaccine which targets tumor-specific neoantigens for the personalized treatment of cancer patients. The BP1209 vaccine is delivered as a molecular complex of patient-specific neoantigen peptides and immune-checkpoint inhibitor antibody such as anti-PD-L1 and anti-CD40 antibodies. The antibody directs the vaccine complex to dendritic cells (DCs) and enhances the cellular vaccine uptake and the antigen-specific T cell priming by suppressing PD-1/PD-L1 signaling or CD40 activation.
The neoantigen peptides consist of three modules: HLA class I and II neoantigen epitopes, and an IgG binding motif. The peptides non-covalently bind Fc domain of IgG, and self-assemble the antibody-vaccine complex without any chemical reaction, which enables individual synthesis and manufacturing of fully personalized neoantigen vaccines. BP1209 strongly enhances antigen-specific immune responses and improves antitumor efficacy using cancer neoantigens. BrightPath has developed proprietary bioinformatics algorithms to identify highly immunogenic neoantigens from cancer patients. The new vaccine platform, BP1209 combined with BrightPath's algorisms for identifying high quality neoantigens provides an ideal option for improving neoantigen vaccine therapy.
Personalized neoantigen cancer vaccine assembled on DC targeting antibody improves cancer immunity
A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity